Assistant Professor, Department of Medicine, D. Y Patil Medical Collage, Kasaba Bawda, Kolhapur, D Y Patil Medical Collage And Hospital, Kadamwadi, Kolhapur, Maharashtra, INDIA.

Email: dr.buddhirajpatil86@gmail.com

REFERENCES

1. C. Rempenault, B. Combe, T. Barnetche et al.., “Clinical and structural efficacy of hydroxychloroquine in rheumatoid arthritis: a systematic review,” Arthritis Care and Research, vol. 72, no. 1, pp. 36–40, 2019.
2. L. Sun, M. Liu, R. Li et al.., “Hydroxychloroquine, a promising choice for coronary artery disease?,” Medical Hypotheses, vol. 93, pp. 5–7, 2016.
3. P. Wang, R. Burikhanov, R. Jayswal et al.., “Neoadjuvant administration of hydroxychloroquine in phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors,” Genes and Cancer, vol. 9, no. 5-6, p. 190, 2018.
4. Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential effect of hydroxychloroquine in diabetes mellitus: a systematic review on preclinical and clinical trial studies. J Diabetes Res. 2020;2020:5214751.
5. Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336-2343.
6. Gupta A. Real-world clinical effectiveness and tolerability of hydroxychloroquine 400 mg in uncontrolled type 2 diabetes subjects who are not willing to initiate insulin therapy (HYQ-real-world study). Curr Diabetes Rev. 2019;15(6):510-519.
7. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol. 2016;12(6):357–70.
8. Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, et al.. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016;5(1):e002867.
9. Kumar, A., and Prakash, A. S. (2019). Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on therapy. Journal of the ASEAN Federation of Endocrine Societies, 34(1), 87.
10. Solomon DH, Garg R, Lu B, et al.. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken). 2014;66 (8):1246-1251.
11. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531.
12. Chen YM, Lin CH, Lan TH, et al.. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015;54(7):1244-1249.
13. Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC. Hydroxychloroquine was associated with reduced risk of newonset diabetes mellitus in patients with Sjögren syndrome. QJM. 2019;112(10):757-762.
14. Pareek A, Chandurkar N, Thomas N, Viswanathan V, Deshpande A, Gupta OP, Shah A, Kakrani A, Bhandari S, Thulasidharan NK, Saboo B. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Current medical research and opinion. 2014 Jul 1;30(7):1257-66.
15. Maiorino MI, Bellastella G, Giugliano D, Esposito K. Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? Endocrine. 2017;55(2):360-5.
16. Salman PM, Quevedo I, Arias M, et al.. Hypoglycemia due to hydroxychloroquine, an uncommon association but to keep in mind, case report and review of literature. J Diabetes Metab Disord Control. 2020;7(1):6‒7.
17. El-Solia A, Al-Otaibi K, Ai-Hwiesh AK. Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis. BMJ Case Rep 2018 Apr. 18;2018.
18. Unübol M, Ayhan M, Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol 2011;17:46-7.
19. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020;192(17):E450-E453
20. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166.
21. Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, et al.. Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases 2020;7:1-9.
22. Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted. N Engl J Med. 2020;382(13):1268-1269.